CEO Lionel Ségard to discuss clinical updates and latest company developments
PARIS and NEW YORK, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced that its Chief Executive Officer, Lionel Ségard, will present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held September 11-13 in New York. This conference is attended by public and private companies, institutional investors, industry executives, scientists, private equity firms, venture capitalists, business development executives and sophisticated private investors.
During his presentation, Mr. Ségard will discuss recent Company developments and anticipated milestones, including updates on the recently-initiated Phase IIa multicentric clinical trial of QGC101, entitled QUID HF (QUantum Genomics Incremental Dosing in Heart Failure), for the treatment of patients with chronic heart failure, the latest developments in its ongoing Phase IIa trial evaluating QG001 for high blood pressure, expanded collaboration agreement with its partner in animal health, and plans for future clinical trials in the U.S.
Details of the presentation are as follows:
Date: Tuesday, September 13
Time: 4:40 pm ET
Location: Adams Room, Lotte New York Palace Hotel
Attendees of the Rodman & Renshaw conference who would like to schedule a 1-on-1 meeting with Quantum Genomics management during the conference may do so by contacting Lee Roth or Joseph Green of The Ruth Group at email@example.com or firstname.lastname@example.org.
For those unable to attend, a live webcast of Mr. Ségard’s presentation will be available at http://wsw.com/webcast/rrshq26/quan. Following his presentation, this webcast will be archived for 90 days.
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
The Company has offices in Paris, France and New York, NY, USA. For more information, please visit www.quantum-genomics.com.
Quantum Genomics Lionel Ségard Chairman & Chief Executive Officer +33 1 85 34 77 77 Quantum Genomics Marc Karako CFO – Investor Relations +33 1 85 34 77 75 email@example.com ACTUS finance et communication (Europe) Jean-Michel Marmillon Press Relations +33 1 53 67 36 73 firstname.lastname@example.org The Ruth Group (U.S.) Lee Roth / Kirsten Thomas Investor / Public Relations +1 646-536-7012 / +1 508-280-6592